JAK2 inhibition for the treatment of hematologic and solid malignancies

Author： Harry Brian L   Eckhardt S. Gail   Jimeno Antonio  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.5, 2012-05, pp. : 637-655

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Entinostat for treatment of solid tumors and hematologic malignancies

By Knipstein Jeffrey   Gore Lia  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 10, 2011-10 ,pp. : 1455-1467

Informa Healthcare

Access to resources Recommend Favorite

Immunotoxins in the Treatment of Hematologic Malignancies

By  

Current Drug Targets, Vol. 7, Iss. 10, 2006-01 ,pp. : 1301-1311

Bentham Science Publishers

Access to resources Recommend Favorite

Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies

By  

Current Pharmaceutical Design, Vol. 15, Iss. 23, 2009-08 ,pp. : 2652-2664

Bentham Science Publishers

Access to resources Recommend Favorite

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies

By Schafer Peter H  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1541-1542

Informa Healthcare

Access to resources Recommend Favorite

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies

By Vallet Sonia   Witzens-Harig Mathias   Jaeger Dirk   Podar Klaus  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 4, 2012-03 ,pp. : 473-494

Informa Healthcare

Access to resources Recommend Favorite